title: Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi.
abstract: We conducted a retrospective analysis on 168 adult patients with newly diagnosed, limited-stage (I and II) diffuse large B-cell lymphoma (DLBCL) treated from 1988 to 2004 with PROMECE-CYTABOM (P-C) plus involved-field radiation therapy (IF-RT). At the end of P-C, the overall response rate was 92%. Radiotherapy (RT) was delivered to 84% of cases. With a median follow-up of 95 months, overall survival (OS), relapse free survival (RFS), and failure free survival at 5 and 10 years was 84% and 77%, 81% and 75%, 71% and 67%, respectively. Age (>60 years, p = 0.002), serum albumin (<3.5 g/dL; p = 0.015), and RT (p < 0.001) were independent predictors of OS. For patients in complete remission the administration of RT didn't improve both RFS and OS. This study confirms that patients with localized aggressive lymphoma have a high chance of cure with anthracycline containing regimens. Though the regimen used to treat these patients does not contain rituximab, results are considered excellent both in terms of efficacy and safety.
authors.affiliation: Divisione di Ematologia, Azienda Ospedaliera Papardo, Messina, Italy.
authors.forename: Donato
authors.initials: D
authors.lastname: Mannina
authors.forename: Stefano
authors.initials: S
authors.lastname: Luminari
authors.forename: Alessandra
authors.initials: A
authors.lastname: Dondi
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Polimeno
authors.forename: Luca
authors.initials: L
authors.lastname: Baldini
authors.forename: Caterina
authors.initials: C
authors.lastname: Stelitano
authors.forename: Francesco
authors.initials: F
authors.lastname: Merli
authors.forename: Matteo
authors.initials: M
authors.lastname: Dell'Olio
authors.forename: Paolo G
authors.initials: PG
authors.lastname: Gobbi
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Giglio
authors.forename: Elisa
authors.initials: E
authors.lastname: Barbolini
authors.forename: Maura
authors.initials: M
authors.lastname: Brugiatelli
authors.forename: Massimo
authors.initials: M
authors.lastname: Federico
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D018572:Disease-Free Survival; D015251:Epirubicin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008223:Lymphoma; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D015999:Multivariate Analysis; D011241:Prednisone / Q000627:therapeutic use; D011878:Radiotherapy / Q000379:methods; D012189:Retrospective Studies; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D003561:Cytarabine; D001761:Bleomycin; D015251:Epirubicin; D014750:Vincristine; D005047:Etoposide; D003520:Cyclophosphamide; D011241:Prednisone; D008727:Methotrexate